LAG3 and neoplasm: The approach of fusing IL-15 to mAbs or their fragments has been increasingly pursued in the last years, however, the targets of these next-generation immunocytokines (e.g., PD-1, PD-L1, LAG3, CD20) are not tumor-specific, but rather broadly expressed on healthy cells.